Drug versus vaccine investment: A modelled comparison of economic incentives

Cost Effectiveness and Resource Allocation

Volumn 11, Issue 1, 2013, Pages

  Régnier, Stéphane A ^a,b   Huels, Jasper ^b  

^a UNIVERSITY OF NEUCHÂTEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drugs; Incentives; Investment; Net present value; Research and development; Vaccines

Indexed keywords

DRUG; VACCINE;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE TRANSMISSION; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; INVESTMENT; RARE DISEASE; VACCINATION;

EID: 84883517682     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-11-23     Document Type: Article

References (27)

1. Berman S, Giffin RB. Global perspectives on vaccine financing. Expert Rev Vaccines 2004, 3:557-562. 10.1586/14760584.3.5.557, 15485335.
2. IMS Institute for Healthcare Informatics Biopharma Forecasts & Trends, April 20, 2010: IMS forecasts global pharmaceutical market growth of 5-8% annually through 2014; maintains expectations of 4-6% growth in 2010 Parsippany, NJ: IMS Institute for Healthcare Informatics, [http://www.theimsinstitute.org], IMS Institute for Healthcare Informatics.
3. Sahoo A. Vaccines 2011: Market analysis, key players and critical trends in a fast-changing industry 2011, Rockville, MD: Kalorama Information.
4. Masignani V, Lattanzi M, Rappuoli R. The value of vaccines. Vaccine 2003, 21(Suppl 2):S110-S113.
5. Rappuoli R, Miller HI, Falkow S. Medicine. The intangible value of vaccination. Science 2002, 297:937-939. 10.1126/science.1075173, 12169712.
6. Whitehead P, Pasternak A. Lessons learned: new procurement strategies for vaccines. Final report to the GAVI Board 2002, Chicago, IL: Mercer Management Consulting, Inc..
7. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach?. Lancet Infect Dis 2008, 8:727-733. 10.1016/S1473-3099(08)70258-5, 18992409.
8. Baumann M. What's behind vaccine shortages? NCPA Brief Analysis No. 655 2009, National Center for Policy Analysis: Dallas, TX.
9. International Society for Pharmacoeconomics and Outcome Research (ISPOR) ISPOR Global Health Care Systems Roadmap Lawrenceville, NJ: ISPOR, [http://www.ispor.org/htaroadmaps/], International Society for Pharmacoeconomics and Outcome Research (ISPOR).
10. Walker D, Beutels P,WHO Initiative for Vaccine Research WHO guide for standardization of economic evaluations of immunization programmes 2008, Geneva: World Health Organization, WHO Initiative for Vaccine Research.
11. Greuel JM. Pharma and biotech: is it possible to keep growing?. Pharma Focus Asia 2008, 6-9. http://www.pharmafocusasia.com/strategy/pharma_biotech_growth.htm.
12. Committee on the Evaluation of Vaccine Purchase Financing in the United States Financing Vaccines in the 21st Century: Assuring Access and Availability 2003, Washington, DC: The National Academies Press, Committee on the Evaluation of Vaccine Purchase Financing in the United States.
13. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185. 10.1016/S0167-6296(02)00126-1, 12606142.
14. Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S, Federico M, Messier M, Kuriyakose S, Hardt K. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: A randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy. Hum Vaccin Immunother 2012, 8:355-362. 3426082, 22327497.
15. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000, 283:2795-2801. 10.1001/jama.283.21.2795, 10838647.
16. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31(23):2638-2646. 10.1016/j.vaccine.2013.03.034, 3743045, 23566946.
17. JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK 2013, [https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf].
18. Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011, 3:79ps13. 10.1126/scitranslmed.3001863, 3616511, 21508308.
19. Cohen J. Shots in the dark: the wayward search for an AIDS vaccine 2001, New York: W. W. Norton & Company.
20. Thomas P. Big shot: passion, politics, and the struggle for an AIDS vaccine 2001, New York: Public Affairs.
21. Harris JE. Why we don't have an HIV vaccine, and how we can develop one. Health Aff (Millwood) 2009, 28:1642-1654.
22. Craddock S. Market incentives, human lives, and AIDS vaccines. Soc Sci Med 2007, 64:1042-1056. 10.1016/j.socscimed.2006.10.006, 17113203.
23. EvaluatePharma [http://www.evaluatepharma.com].
24. Howden LM, Meyer JA. Age and sex composition: 2010 2011, Washington, DC: U.S. Census Bureau, 2010 Census Briefs.
25. Centers for Disease Control and Prevention Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2010: HIV Surveillance Report, Vol. 22. February 2011 Atlanta, GA: Centers for Disease Control and Prevention, [http://www.cdc.gov/hiv/surveillance/resources/reports/2010report/index.htm], Centers for Disease Control and Prevention.
26. Lattanzi M, Rappuoli R. Long-term solutions for the problem of vaccine shortages. Expert Opin Biol Ther 2004, 4:989-992. 10.1517/14712598.4.6.989, 15174980.
27. Thompson H. Nature News Blog: United States launches three biodefence centres London: Nature Publishing Group, [http://blogs.nature.com/news/2012/06/us-launches-three-biodefense-centres.html].